

Secretary of the State File Number

6466

Regulation of the

Department of Consumer Protection

Concerning

Controlled Substances Drug Schedule Updates

Regulations adopted after July 1, 2013, become effective upon posting to the Connecticut eRegulations System, or at a later date if specified within the regulation.

Posted to the Connecticut eRegulations System on **April 2, 2026**

EFFECTIVE DATE

April 2, 2026

Approved by the Attorney General on

December 22, 2025

Approved by the Legislation Regulation Review Committee on

February 24, 2026

Electronic copy with agency head certification statement electronically submitted to and received by the Office of the Secretary of the State on

March 25, 2026

Form ICM-ECOPY (NEW 6/2015)
State of Connecticut
Secretary of the State



IMPORTANT NOTICE FOR CONNECTICUT STATE AGENCIES
This form should be used only for regulations first noticed *on and after March 23, 2015*.

Electronic Copy Certification Statement

(Submitted in accordance with the provisions of section 4-172 of the Connecticut General Statutes)

Regulation of the
Department of Consumer Protection
Concerning
Controlled Substance Drug Schedule Updates

Approved by the Legislative Regulation Review Committee: **February 26, 2026**

eRegulations System Tracking Number: **PR2025-018**

I hereby certify that the electronic copy of the above-referenced regulation submitted herewith to the Secretary of the State is a true and accurate copy of the regulation approved in accordance with sections 4-169 and 4-170 of the *Connecticut General Statutes*.

And I further certify that in accordance with the approval of Legislative Regulation Review Committee, all required technical corrections, page substitutions and deletions, if any, have been incorporated into said regulation.

In testimony whereof, I have hereunto
set my hand on **March 25, 2026**.

/s/

M. Caitlin S. Anderson
Chief of Legal and Regulatory Affairs
Department of Consumer Protection

STATE OF CONNECTICUT
Regulation of
Department of Consumer Protection
concerning
Controlled Substance Drug Schedule Updates

Section 1. Section 21a-243-7 of the Regulations of Connecticut State Agencies is amended to read as follows:

Sec. 21a-243-7. Controlled substances in schedule I

The controlled substances listed in this regulation are included by whatever official, common, usual, chemical, or trade name designation in schedule I:

(a) Unless specifically excepted or unless listed in another schedule in the Connecticut General Statutes, or the regulations promulgated thereunder, or by the Food and Drug Administration, any [Any] of the following opiates, including their isomers, esters, ethers, salts and salts of isomers, esters and ethers, [unless specifically excepted,] whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation:

- (1) Acetylalpha-methylfentanyl;
- (2) Acetylmethadol;
- (3) Allylprodine;
- (4) Alphacetylmethadol (except Levo-alphacetylmethadol or LAAM);
- (5) Alphameprodine;
- (6) Alphamethadol;
- (7) Alpha-methylfentanyl;
- (8) Alphamethylthiofentanyl;
- (9) Benzethidine;
- (10) Betacetylmethadol;
- (11) Beta-hydroxy-fentanyl;
- (12) Beta-hydroxy-3-methylfentanyl;
- (13) Betameprodine;
- (14) Betamethadol;
- (15) Betaprodine;
- (16) Clonitazene;
- (17) Dextromoramide;
- (18) Diampromide;
- (19) Diethylthiambutene;
- (20) Difenoxin;
- (21) Dimenoxadol;

- (22) Dimepheptanol;
- (23) Dimethylthiambutene;
- (24) Dioxaphetyl Butyrate;
- (25) Dipipanone;
- (26) Ethylmethylthiambutene;
- (27) Etonitazene;
- (28) Etoxidine;
- (29) Furethidine;
- (30) Hydroxypethidine;
- (31) Ketobemidone;
- (32) Levomoramide;
- (33) Levophenacymorphan;
- (34) 3-methylfentanyl;
- (35) 3-methylthiofentanyl;
- (36) Morpheridine;
- (37) Noracymethadol;
- (38) Norlevorphanol;
- (39) Normethadone;
- (40) Norpipanone;
- (41) Para-fluorofentanyl;
- (42) PEPAP (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
- (43) Phenadoxone;
- (44) Phenampromide;
- (45) Phenomorphan;
- (46) Phenoperidine;
- (47) Piritramide;
- (48) Proheptazine;
- (49) Properidine;
- (50) Propiram;
- (51) Racemoramide;
- (52) Thiofentanyl;
- (53) Tilidine;
- (54) Trimeperidine.

(b) Unless specifically excepted or unless listed in another schedule in the Connecticut General Statutes, or the regulations promulgated thereunder, or by the Food and Drug Administration, any [Any] of the following opium derivatives, including their salts, isomers and salts of isomers, [unless specifically excepted] whenever the existence of these salts, isomers and salts of isomers is possible within the specific chemical designation:

- (1) Acetorphine;

- (2) Acetyldihydrocodeine;
- (3) Benzylmorphine;
- (4) Codeine methylbromide;
- (5) Codeine-N-oxide;
- (6) Cyprenorphine;
- (7) Desomorphine;
- (8) Dihydromorphine;
- (9) Drotebanol;
- (10) Etorphine, except hydrochloride salts;
- (11) Heroin;
- (12) Hydromorphanol;
- (13) Methyldesorphine;
- (14) Methyldihydromorphine;
- (15) Morphine methylbromide;
- (16) Morphine methylsulfonate;
- (17) Morphine-N-oxide;
- (18) Myrophine;
- (19) Nicocodeine;
- (20) Nicomorphine;
- (21) Normorphine;
- (22) Pholcodine;
- (23) Thebacon.

(c) Unless specifically excepted or unless listed in another schedule in the Connecticut General Statutes, or the regulations promulgated thereunder, or by the Food and Drug Administration, any [Any] material, compound, mixture or preparation which contains their salts, isomers and salts of isomers, [unless specifically excepted,] whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation:

- (1) Alpha-ethyltryptamine;
- (2) 4-bromo-2,5-dimethoxyamphetamine; or 4-bromo-2,5-DMA;
- (3) 2,5-dimethoxyamphetamine; or 2,5-DMA;
- (4) 2,5-Dimethoxy-4-ethylamphetamone or DOET;
- (5) 3,4-M ethylenedioxy-N-ethylamphetamine;
- (6) 1-methyl-4-phenyl-4-propionoxypiperidine; or MPPP;
- (7) 3,4-methylenedioxymethamphetamine; or MDMA;
- (8) 2,5-dimethoxy-4-(n)-propylthiopenenthylamine (2C-T-7);
- (9) 4-methoxyamphetamine; or PMA;
- (10) 5-methoxy-3,4-methylenedioxy-amphetamine;
- (11) 5-Methoxy-nn-Diisopropyltryptamine(5-methoxy-dipty);
- (12) 4-methyl-2,5-dimethoxyamphetamine; or DOM; or STP;

- (13) 3,4-methylenedioxy amphetamine; or MDA;
- (14) N-hydroxy-3,4-methylenedioxyamphetamine (also known as N-hydroxy-alpha- methyl-3,4(methylenedioxy)phenethylamine, and N-hydroxy MDA;
- (15) 3,4,5-trimethoxy amphetamine;
- (16) benzylpiperazine or BZP;
- (17) Bufotenine or Mappine;
- (18) Alphaethyltryptamine;
- (19) Diethyltryptamine or DET;
- (20) Dimethyltryptamine or DMT;
- (21) Ibogaine;
- (22) Lysergic acid diethylamide;
- (23) MDVP (3,4-methylenedioxypropionylpyrovalerone);
- (24) 3,4-methylenedioxy-N-methylcathinone (methydone);
- (25) Mephedrone (4-methylmethcathinone);
- (26) Mescaline;
- (27) Parahexyl or Synhexyl;
- (28) Peyote, meaning all parts of the plants;
- (29) 1-(2-phenylethyl)-4-phenyl-4-acetoxypiperidine; or PEPAP;
- (30) N-ethyl-3-piperidyl benzilate;
- (31) N-methyl-3-piperidyl benzilate;
- (32) Psilocybin;
- (33) Psilocyn;
- (34) Tetrahydrocannabinols except Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a United States food and drug administration approved product;
- (35) Salvia divinorum;
- (36) Salvinorin A;
- (37) Ethylamine analog of phencyclidine, Cyclohexamine or PCE;
- (38) 4-Bromo-2,5-dimethoxyphenethylamine;
- (39) Pyrrolidine analog of phencyclidine, PCP or PHP;
- (40) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine;
- (41) Thiophene analog of phencyclidine, TPCP or TCP;
- (42) Tiletamine or 2-(ethylamino)-2-(2-thienyl)-cyclohexanone;
- (43) Trifluoromethylphenylpiperazine or TFMPP; [.]
- (44) 7-hydroxymitragynine;
- (45) Bromazolam;
- (46) Flubromazolam;
- (47) Mitragyna speciosa (kratom), including its leaves, stem and any extracts;
- (48) Nitazenes, including, but not limited to, isotonitazene;
- (49) Tianeptine; and

(50) Phenibut.

(d) Unless specifically excepted or unless listed in another schedule in the Connecticut General Statutes, or the regulations promulgated thereunder, or by the Food and Drug Administration, any [Any] material, compound, mixture or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including their salts, isomers and salts of isomers [unless specifically excepted], wherever the existence of these salts, isomers and salts of isomers is possible within the specific chemical designation:

(1) Gamma-hydroxy butyric acid, except if contained in a drug product for which an application has been approved under section 505 of the Food, Drug and Cosmetic Act;

(2) Gamma-butyrolactone;

(3) Mecloqualone;

(4) Methaqualone; or

(5) Zolazepam.

(e) Unless specifically excepted or unless listed in another schedule in the Connecticut General Statutes, or the regulations promulgated thereunder, or by the Food and Drug Administration, any material, compound, mixture or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers:

(1) Aminorex;

(2) N-benzylpiperazine (some other names: BZP; 1-benzylpiperazine);

(3) 4-Methylaminorex;

(4) Cathinone;

(5) Fenethylamine;

(6) Methcathinone;

(7) N-ethylamphetamine;

(8) N,N-Dimethylamphetamine.

(f) Unless specifically excepted or unless listed in another schedule in the Connecticut General Statutes, or the regulations promulgated thereunder, or by the Food and Drug Administration, any material, compound, mixture or preparation which contains any quantity of a substance having a psychotropic response primarily by agonist activity at cannabinoid-specific receptors affecting the central nervous system. Specific compounds include, but are not limited to:

(1) 1-pentyl-3-(1-naphthoyl)indole (JWH-018);

(2) 1-butyl-3-(1-naphthoyl)indole (JWH-073);

(3) 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200);

(4) 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP-47,497);

(5) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabi-cyclohexanol CP-47,497 C8 homologue).

(g) Any schedule I controlled substance, used for a medical purpose under the supervision of a practitioner, that has been approved by the federal Food and Drug Administration, or successor agency, to have a medical use and is reclassified in any schedule of the controlled substances or unscheduled under the federal Controlled Substances Act shall have the same designation for state purposes as that designated under the federal Controlled Substances Act, unless otherwise

specifically designated by the Commissioner of Consumer Protection in accordance with section 21a-243 of the Connecticut General Statutes.

Statement of Purpose

The purpose of this regulation is to designate new substances to the controlled substance list as required by Public Act 25-101, Section 4. This new law requires the Commissioner of Consumer Protection to designate the substances added to subsection (i) of that section as controlled substances and classify each such substance in the appropriate schedule. Since such substances currently have no medical use, pursuant to the Federal Drug Administration (FDA), and may not be prescribed or dispensed by a medical professional, the Department of Consumer Protection proposes this regulation to place the substances in schedule 1. However, if any of the substances are rescheduled by the FDA, this regulation contains an existing provision in subsection (g) to adopt the schedule determined by the FDA.



IMPORTANT NOTICE FOR CONNECTICUT STATE AGENCIES

This form is to be used for proposed permanent and technical amendment regulations only and must be completed in full.

AGENCY CERTIFICATION

Department of Consumer Protection

Proposed Regulation Concerning

Controlled Substances Drug Schedule Updates

eRegulations System Tracking Number **PR2025-018**

I hereby certify the following:

(1) The above-referenced **regulation** is proposed pursuant to the following statutory authority or authorities: **Conn. Gen. Stat. Section 21a-243; Public Act 25-101, Section 4, Subsection (i)**

For technical amendment regulations proposed without a comment period, complete #2 below, then skip to #8.

(2) As permitted by Section 4-168(h) of the *Connecticut General Statutes*, the agency elected to proceed without prior notice or hearing and posted the text of the proposed technical amendment regulation on eRegulations System website on **n/a**.

For all other non-emergency proposed regulations, complete #3 - #7 below, then complete #8)

(3) The agency posted notice of intent with a specified comment period of not less than 30 days to the eRegulations System website on **September 18, 2025**.

(4) *(Complete one)* No public hearing held or was required to be held. **OR** One or more public hearings were held on: **October 15, 2025**.

(5) The agency posted notice of decision to move forward with the proposed regulation to the eRegulations System website on **December 10, 2025**.

(6) *(Complete one)* No comments were received. **OR** Comments were received and the agency posted the statements specified in subdivisions (1) and (2) of CGS Section 4-168(e) to the eRegulations System website on **December 10, 2025**.

(7) The final wording of the proposed regulation was posted to the eRegulations System website on **September 18, 2025**.

(8) Subsequent to approval for legal sufficiency by the Attorney General and approval by the Legislative Regulation Review Committee, **the final regulation shall be effective**

(Check one and complete as applicable)

When posted to the eRegulations System website by the Secretary of the State.

OR On _____

(Date must be a specific calendar date not less than 11 days after submission to the Secretary of the State)

Chief of Legal & Regulatory Affairs

12/11/2025

SIGNED

(Head of Board, Agency or Commission, or duly authorized deputy)

OFFICIAL TITLE

DATE


**OFFICE OF THE ATTORNEY GENERAL
REGULATION CERTIFICATION**

Agency: Department of Consumer Protection

REGULATION NUMBER PR2025-018

This Regulation is hereby APPROVED by the Attorney General as to legal sufficiency in accordance with Connecticut General Statutes § 4-169.

DATE: 12/22/2025

Signed: 

***Sean Kehoe, Associate Attorney General
Chief of the Division of Government Administration
Duly Authorized***

The Connecticut General Assembly

Legislative Regulation Review Committee

Senator Sujata Gadkar-Wilcox
Senate Chair



Representative Christie Carpino
House Chair

Official Record of Committee Action

February 24, 2026

Agency: Department of Consumer Protection
Description: Controlled Substance Drug Schedule Updates
LRRC Regulation Number: 2026-003
eRegulation Tracking Number: PR2025-018

The above-referenced regulation has been

Approved with Technical Corrections

by the Legislative Regulation Review Committee in accordance
with CGS Section 4-170.

Catherine M. Thomas
Committee Administrator



State of Connecticut
Office of the Secretary of the State

Confirmation of Electronic Submission

Re: Regulation of the Department of Consumer Protection concerning Controlled Substances Drug Schedule Updates
eRegulations System Tracking Number PR2025-018
Legislative Regulation Review Committee Docket Number 2026-003

The above-referenced regulation was electronically submitted to the Office of the Secretary of the State in accordance with Connecticut General Statutes Section 4-172 on March 25, 2026.

Said regulation is assigned Secretary of the State File Number 6466.

The effective date of this regulation is April 2, 2026.

A handwritten signature in blue ink, appearing to read "Stephanie Thomas".

Stephanie Thomas
Secretary of the State
April 2, 2026

By:

/s/ Christopher R. Drake
Christopher R. Drake
Director, Business Services
Division